The fight against one of the world’s most common respiratory viruses just got another weapon.
On Monday, the FDA approved Beyfortus, an antibody drug co-developed by Sanofi and AstraZeneca. Beyfortus, also known as nirsevimab, is given as a one-time intramuscular injection to infants, protecting them from respiratory syncytial virus, or RSV. The drug won European approval in November.
Beyfortus is the latest in a suite of new medicines against RSV, a virus that typically puts 58,000 to 80,000 young children in the US in the hospital every year. Earlier this year, the FDA approved two RSV vaccines for older adults: GSK’s Arexvy and Pfizer’s Abrysvo. Wall Street analysts expect all these new medicines to grow into blockbusters over the next decade.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
Health - Latest - Google News
July 18, 2023
https://ift.tt/Hh7cnI5
FDA approves another RSV option, this time it's Sanofi and AstraZeneca's antibody drug for infants - Endpoints News
Health - Latest - Google News
https://ift.tt/nb9ePXN
Bagikan Berita Ini
0 Response to "FDA approves another RSV option, this time it's Sanofi and AstraZeneca's antibody drug for infants - Endpoints News"
Post a Comment